Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Canada
First Oral Precision Medicine for Fabry Disease with Broad Label for Fabry Patients with Amenable Genetic Mutations
View HTML
Toggle Summary Amicus Therapeutics Announces Top-Line Phase 3 Results for SD-101 in Epidermolysis Bullosa
Study Did Not Meet Primary Endpoints Conference Call and Webcast Today at 8:30am ET CRANBURY, N.J. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics , Inc. (Nasdaq:FOLD) reported that top-line data from the randomized, double-blind, placebo-controlled Phase 3 clinical study (ESSENCE, SD-005)
View HTML
Toggle Summary Amicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
CRANBURY, N.J. , Aug. 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that 6 posters highlighting its Fabry program will be included in the 13 th International Congress of Inborn Errors of Metabolism to be held September 5-8, 2017 in Rio de Janeiro, Brazil .
View HTML
Toggle Summary Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Australia
First Amicus Medicine and First Oral Precision Medicine for Fabry Disease in Australia Broad Label for Fabry Patients with an Amenable Genetic Mutation CRANBURY, N.J. , Aug. 15, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Australian Therapeutic Goods Administration
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
             179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 - On Target to Reach 300 Patients by Year-End 2017 Migalastat NDA Submission Targeted for 4Q17 Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17 CRANBURY, N.J. , Aug.
View HTML
Toggle Summary Amicus Therapeutics to Announce Second Quarter 2017 Financial Results on August 7, 2017
CRANBURY, N.J. , July 25, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on August 7, 2017 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2017 . The call will be hosted by John F.
View HTML
Toggle Summary Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
CRANBURY, N.J. , July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock.
View HTML
Toggle Summary Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J. , July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 18,367,347 shares of its common stock at $12.25 per share.
View HTML
Toggle Summary Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J. , July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $225 million underwritten public offering of its common stock. J.P.
View HTML
Toggle Summary U.S. FDA Confirms Amicus Therapeutics May Submit New Drug Application for Migalastat for Fabry Disease
Data Deemed Sufficient to Support NDA Submission NDA Submission Targeted for 4Q17 Conference Call Today at 8:30am ET CRANBURY, N.J. , July 11, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) plans to submit a new drug application (NDA) to the U.S.
View HTML